Qualigen Therapeutics, Inc. Common Stock (QLGN) EBITDA (2020 - 2025)
Qualigen Therapeutics, Inc. Common Stock (QLGN) EBITDA from Jun 30, 2020 to Sep 30, 2025. The TTM Qualigen Therapeutics, Inc. Common Stock (QLGN) EBITDA is -$7.16M. You can adjust inflation or export chart.
Annual EBITDA
Quarterly EBITDA
Qualigen Therapeutics, Inc. Common Stock (QLGN) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +6.87% |
| 3 Years TTM | -25.29% |
| 5 Years TTM | +2.82% |
| All Time TTM | -18.09% |
Annual EBITDA change of Qualigen Therapeutics, Inc. Common Stock (QLGN)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$5.83M | +1.22% |
| 2024 | -$5.76M | -49.03% |
| 2023 | -$11M | -23.39% |
| 2022 | -$15M | -33.92% |
| 2021 | -$22M | +258.27% |
| 2020 | -$6.23M | N/A |